Real Imaging

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

FMI Medical Systems specializes in the development and design of high-end medical imaging equipment within the healthcare technology sector. The company's main offerings include computed tomography (CT) systems and positron emission tomography/computed tomography (PET/CT) systems, which are used for advanced medical diagnostics. FMI primarily serves the healthcare industry, providing imaging solutions for clinical and molecular applications. It is based in Akron, Ohio.

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Seno Medical develops opto-acoustic imaging technology for breast cancer diagnostics in the medical device industry. The Imagio® Breast Imaging System combines laser light and ultrasound to provide functional and anatomical imaging, aimed at increasing the accuracy of breast cancer diagnosis and decreasing the number of negative biopsies. The system is intended to assist radiologists in the diagnostic process. It was founded in 2005 and is based in San Antonio, Texas.

MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n

Micrima develops a non-invasive imaging tool, Mi~Scan, designed to analyze breast tissue properties for early detection of breast cancer. The technology is utilized in the healthcare industry to aid in informed decision-making in women's healthcare. It was founded in 2006 and is based in Bristol, England.